跳至主要内容
临床试验/NL-OMON44175
NL-OMON44175已完成不适用

Mindfulness Based Cognitive Therapy for bipolar disorder - MBCT for bipolar disorder

Radboudumc0 个研究点目标入组 144 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Radboudumc
入组人数
144

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - bipolar I or II disorder
  • - having suffered at least two lifetime depressive episodes, either current or in (partial) remission at baseline (according to SCID assessment)
  • -having suffered at least one episode (depressed or (hypo)manic) within the year prior to baseline.
  • - Young Mania Rating Scale score < 8

排除标准

  • - a (hypo)manic episode in the 3 months before the start of the trial
  • - lifetime diagnosis of schizophrenia or schizoaffective disorder, current substance abuse disorder, organic brain syndrome, antisocial or borderline personality disorder
  • - risk of suicide or aggression
  • - the presence of a concurrent significant medical condition impeding the ability to participate

研究者

发起方
Radboudumc

相似试验

已完成
不适用
Quality of life and benefit for patients: bipolar radiofrequency-induced thermotherapy (RFITT) versus crossectomy and strippingGreat saphenous vein insufficiencyCirculatory SystemVenous insufficiency (chronic) (peripheral)
ISRCTN11604626Artemed SE (Germany)200
进行中(未招募)
1 期
Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores
EUCTR2017-005059-10-BEGhent University Hospital180
已完成
2 期
Double-Blind Naltrexone in KleptomaniaKleptomania
NCT00332579University of Minnesota25
进行中(未招募)
Unknown
Efficacy of an organic pomegranate polyphenol complex (VIQUA®) in type 1 primary osteoporosis in post-menopausal womePrevention of osteoporosis in postmenopausal womenMusculoskeletal Diseases
ISRCTN13473651INNOVATION LABO Sciences Co., Ltd60
进行中(未招募)
不适用
In this clinical study, a new drug, Budesonid 3 mg effervescent tablet for the preparation of a mouth rinse solution to treat oral chronic GvHD (Graft versus Host Disease) resulting from allogeneic (taken from different individuals of the same species) haematopoietic (blood cell forming) stem cell transplantation (HSCT), is evaluated.Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.MedDRA version: 16.0Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disorders
EUCTR2008-004562-10-CZDr. Falk Pharma GmbH224